Abbvie Inc.

Abbott Laboratories Corporation

Other

Wisconsin Alumni Research Foundation

Abbvie Deutschland Gmbh and Co Kg

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Geoff G Zhang

Yuchuan Gong

Shuang Chen

David M Barnes

Anthony Ralph Haight

Rodger F Henry

Brian J Kotecki

John K Pratt

Rolf Wagner

Todd Warren Rockway

John T Randolph

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Allan C Krueger

Clarence J Maring

Kent D Stewart

Kenton L Longenecker

Pamela L Donner

Thomas B Borchardt

Madhup K Dhaon

Nathaniel Catron

Michael Rasmussen

Yaya Liu

Robert M Leanna

John E Hengeveld

Shekhar Viswanath

Larry Bartelt

Warren M Kati

Charles A Flentge

Christopher E Motter

Yi Shi

Ping Gao

David A Degoey

Philip R Kym

Valentino J Stella

Peter T Mayer

Yi Gao

Eric A Voight

Mark A Matulenko

Vincent S Chan

Yanbin Lao

Xiaochun Lou

Ye Huang

Sean E Mackey

Zhi Wang

Russell C Klix

Jianwei Wu

Christopher P Miller

Markus Maegerlein

James Patrick Stambuli

Brian P Enright

Raimundo Ho

Alexander D Huters

Scott W Krabbe

Yanxia Li

Benoit Cardinal-David

Jianguo Ji

Jonathan Miller

Ahmad Y Sheikh

Michael D Tufano

Steven J Wittenberger

Jayanthy Jayanth

Michael F Bradley

Kennan C Marsh

Eric Allen Schmitt

Steven M Hannick

Timothy A Robbins

Seble H Wagaw

Paul J Brackemeyer

Wenke Li

Timothy B Towne

Ping Tong

Matthias Degenhardt

John B Morris

Sean M Mellican

Lian Yu

David R Willcox

Jeffrey M Breting

Katherine E Peterson

Martin Babcock

Douglas H Hoffman

John Pavlina

Adivaraha Jayasankar

Michael J Buckley

Bryan S Macri

Samrat Mukherjee

John C Strong

Agnes E Pal

Huailiang Wu

Hao Hou

Ameesha Patel

David Beno

Jing Tao

Ye Sun

Maurizio Acquasaliente

Didier Houllemare

Pulla Singam

Yi Goa

Moiz Diwan

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Salts and crystalline forms of an apoptosis-inducing agent

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

Formulations of pyrimidinedione derivative compounds

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Carbidopa and L-dopa prodrugs and methods of use

A process for acoustically mixing a bulk drug substance involves the application of acoustic energy to drive an accelerative force in a mixing vessel containing the drug substance. The drug substance may be, for example, Elagolix.

Acoustic mixing for auto granulation

The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.

Atrasentan mandelate salts

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (&#xb0; 2&#x3b8;) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.

Crystaline forms of HCV inhibitor

A pharmaceutical product comprising at least one phenyl uracil-based pharmaceutically active agent or an agent of related structural type and processes for obtaining such product.

Formulations of phenyl uracil compounds

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.

Crystalline lopinavir/surfactant adducts

The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices. The method relies on the detection of the dissolution endpoint of a drug/polymer mixture prepared by cryomilling.

Method for evaluating the solubility of a crystalline substance in a polymer

Growing community of inventors

Vernon Hills, IL, United States of America

Geoff G Zhang